Report cover image

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 115 Pages
SKU # APRC20352111

Description

Summary

According to APO Research, the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment include Astellas, Boehringer Ingelheim, Chugai Pharmaceutical, Taisho Pharmaceutical, AstraZeneca, Jiangsu Hengrui Medicine, Merck, Johnson & Johnson and Sanofi, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding SGLT-2 Inhibitors for Type 2 Diabetes Treatment.

The report will help the SGLT-2 Inhibitors for Type 2 Diabetes Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The SGLT-2 Inhibitors for Type 2 Diabetes Treatment market size, estimations, and forecasts are provided in terms of sales volume (M Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Company

Astellas
Boehringer Ingelheim
Chugai Pharmaceutical
Taisho Pharmaceutical
AstraZeneca
Jiangsu Hengrui Medicine
Merck
Johnson & Johnson
Sanofi
SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Type

Canagliflozin
Empagliflozin
Dapagliflozin
Others
SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Application

E-commerce and Internet Medical Care
Offline Retail Pharmacy
Hospitals and Clinics
SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of SGLT-2 Inhibitors for Type 2 Diabetes Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SGLT-2 Inhibitors for Type 2 Diabetes Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of SGLT-2 Inhibitors for Type 2 Diabetes Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of SGLT-2 Inhibitors for Type 2 Diabetes Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of SGLT-2 Inhibitors for Type 2 Diabetes Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

115 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size (2020-2031)
2.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (2020-2031)
2.2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Average Price (2020-2031)
2.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Canagliflozin
2.3.3 Empagliflozin
2.3.4 Dapagliflozin
2.3.5 Others
2.4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 E-commerce and Internet Medical Care
2.4.3 Offline Retail Pharmacy
2.4.4 Hospitals and Clinics
3 Market Competitive Landscape by Manufacturers
3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs) of Manufacturers (2020-2025)
3.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue of Manufacturers (2020-2025)
3.4 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Average Price by Manufacturers (2020-2025)
3.5 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Product Type & Application
3.8 Global Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Established Date
3.9 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Astellas
4.1.1 Astellas Company Information
4.1.2 Astellas Business Overview
4.1.3 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
4.1.5 Astellas Recent Developments
4.2 Boehringer Ingelheim
4.2.1 Boehringer Ingelheim Company Information
4.2.2 Boehringer Ingelheim Business Overview
4.2.3 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
4.2.5 Boehringer Ingelheim Recent Developments
4.3 Chugai Pharmaceutical
4.3.1 Chugai Pharmaceutical Company Information
4.3.2 Chugai Pharmaceutical Business Overview
4.3.3 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
4.3.5 Chugai Pharmaceutical Recent Developments
4.4 Taisho Pharmaceutical
4.4.1 Taisho Pharmaceutical Company Information
4.4.2 Taisho Pharmaceutical Business Overview
4.4.3 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
4.4.5 Taisho Pharmaceutical Recent Developments
4.5 AstraZeneca
4.5.1 AstraZeneca Company Information
4.5.2 AstraZeneca Business Overview
4.5.3 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)
4.5.4 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
4.5.5 AstraZeneca Recent Developments
4.6 Jiangsu Hengrui Medicine
4.6.1 Jiangsu Hengrui Medicine Company Information
4.6.2 Jiangsu Hengrui Medicine Business Overview
4.6.3 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
4.6.5 Jiangsu Hengrui Medicine Recent Developments
4.7 Merck
4.7.1 Merck Company Information
4.7.2 Merck Business Overview
4.7.3 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
4.7.5 Merck Recent Developments
4.8 Johnson & Johnson
4.8.1 Johnson & Johnson Company Information
4.8.2 Johnson & Johnson Business Overview
4.8.3 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
4.8.5 Johnson & Johnson Recent Developments
4.9 Sanofi
4.9.1 Sanofi Company Information
4.9.2 Sanofi Business Overview
4.9.3 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
4.9.5 Sanofi Recent Developments
5 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Scenario by Region
5.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2020-2031
5.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2020-2025
5.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2026-2031
5.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2020-2031
5.3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2020-2025
5.3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2026-2031
5.4 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
5.4.1 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2031)
5.4.3 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
5.5.1 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2031)
5.5.3 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
5.6.1 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2031)
5.6.3 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
5.7.1 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2031)
5.7.3 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.7.7 Colombia
5.8 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
5.8.1 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2031)
5.8.3 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2020-2031)
6.1.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2020-2031) & (M Pcs)
6.1.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2020-2031)
6.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2020-2031)
6.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2020-2031)
6.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type (2020-2031)
7 Segment by Application
7.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2020-2031)
7.1.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2020-2031) & (M Pcs)
7.1.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2020-2031)
7.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2020-2031)
7.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2020-2031)
7.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Value Chain Analysis
8.1.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process
8.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Distributors
8.2.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Customers
9 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Analyzing Market Dynamics
9.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Trends
9.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Drivers
9.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges
9.4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.